Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1L1 | Q9UHC9 | 9/20 | 0.56 |
| ▸ | USP2 | O75604 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | CDC25A | P30304 | 5/20 | 0.54 |
| ▸ | POLA1 | P09884 | 1/20 | 0.54 |
| ▸ | VDR | P11473 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | FNTA | P49354 | 1/20 | 0.47 |
| ▸ | FNTB | P49356 | 1/20 | 0.47 |
| ▸ | INPP5D | Q92835 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acebrochol SCHEMBL9250494 | 1.00 | NPC1L1 (0.56) | NPC1L1USP2LMNAMEN1TP53 | |
| Acebrochol SCHEMBL30009744 | 1.00 | NPC1L1 (0.56) | NPC1L1USP2LMNAMEN1TP53 | |
| SCHEMBL21814362 | 0.92 | NPC1L1 (0.62) | NPC1L1USP2LMNAMEN1TP53 | |
| SCHEMBL21814361 | 0.92 | NPC1L1 (0.62) | NPC1L1USP2LMNAMEN1TP53 | |
| SCHEMBL9250800 | 0.91 | NPC1L1 (0.56) | NPC1L1USP2LMNAMEN1TP53 | |
| SCHEMBL18918658 | 0.85 | NPC1L1 (0.69) | NPC1L1USP2LMNAMEN1TP53 | |
| SCHEMBL18942513 | 0.85 | NPC1L1 (0.69) | NPC1L1USP2LMNAMEN1TP53 | |
| SCHEMBL1274095 | 0.85 | NPC1L1 (0.69) | NPC1L1USP2LMNAMEN1TP53 | |
| SCHEMBL23628419 | 0.83 | NPC1L1 (0.64) | NPC1L1USP2LMNAMEN1TP53 | |
| SCHEMBL6300889 | 0.83 | NPC1L1 (0.55) | NPC1L1USP2LMNAMEN1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250032510-A1 | AMORPHOUS SOLID DISPERSION GANAXOLONE FORMULATION | IMMEDICA PHARMA US INC. | 2025-01-30 | — | — | US | claimed |
| WO-2023060067-A1 | AMORPHOUS SOLID DISPERSION GANAXOLONE FORMULATION | MARINUS PHARMACEUTICALS, INC. (US) | 2023-04-13 | — | — | WO | claimed |
| US-20220023314-A1 | STABLE FORMULATIONS OF ANESTHETICS AND ASSOCIATED DOSAGE FORMS | Halo Science LLC | 2022-01-27 | — | — | US | claimed |
| EP-3893847-A1 | STABLE FORMULATIONS OF ANESTHETICS AND ASSOCIATED DOSAGE FORMS | Halo Science LLC (US) | 2021-10-20 | — | — | EP | claimed |
| WO-2020123551-A1 | STABLE FORMULATIONS OF ANESTHETICS AND ASSOCIATED DOSAGE FORMS | Halo Science LLC (US) | 2020-06-18 | — | — | WO | claimed |
| CN-110520131-A | The neurosteroid preparation of sustained release injectable | MARINUS PHARMACEUTICALS INC | 2019-11-29 | — | — | CN | claimed |
| US-20190321375-A1 | METHOD OF ADMINISTERING A NEUROSTEROID TO EFFECT ELECTROENCEPHALOGRAPHIC (EEG) BURST SUPPRESSION | MARINUS PHARMACEUTICALS INC (US) | 2019-10-24 | — | — | US | claimed |
| EP-3525797-A1 | METHOD OF ADMINISTERING A NEUROSTEROID TO EFFECT ELECTROENCEPHALOGRAPHIC (EEG) BURST SUPPRESSION | Marinus Pharmaceuticals, Inc. (US) | 2019-08-21 | — | — | EP | claimed |
| CN-109890392-A | Method of the application neurosteroid to realize electroencephalogram (EEG) outburst inhibition | 马瑞纳斯制药公司 | 2019-06-14 | — | — | CN | claimed |
| US-20180296487-A1 | SUSTAINED RELEASE INJECTABLE NEUROSTEROID FORMULATIONS | MARINUS PHARMACEUTICALS INC (US) | 2018-10-18 | — | — | US | claimed |
| US-8975245-B2 | Anaesthetic formulation | DRAWBRIDGE PHARMACEUTICALS PTY LTD (AU) | 2015-03-10 | — | — | US | claimed |
| US-20140066417-A1 | ANAESTHETIC FORMULATION | DRAWBRIDGE PHARMACEUTICALS PTY LTD (AU) | 2014-03-06 | — | — | US | claimed |
| US-20120316146-A1 | ANAESTHETIC FORMULATION | MONASH UNIVERSITY (AU) | 2012-12-13 | — | — | US | claimed |
| CN-102802635-A | Anaesthetic formulation | GOODCHILD INVEST PTY LTD | 2012-11-28 | — | — | CN | claimed |
| WO-2011088503-A1 | ANAESTHETIC FORMULATION | GOODCHILD INVESTMENTS PTY LTD (AU) | 2011-07-28 | — | — | WO | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190321375-A1 | METHOD OF ADMINISTERING A NEUROSTEROID TO EFFECT ELECTROENCEPHALOGRAPHIC (EEG) BURST SUPPRESSION | SCN11A, SCN10A, PYGB | NPC1L1 2469/4885USP2 2258/4885LMNA 2743/4885 |
| US-20180296487-A1 | SUSTAINED RELEASE INJECTABLE NEUROSTEROID FORMULATIONS | SCN10A, THRA, TSHR | NPC1L1 1573/4885USP2 3527/4885LMNA 2060/4885 |
| US-20120316146-A1 | ANAESTHETIC FORMULATION | OPRL1, CNR1, CNR2 | NPC1L1 430/4885USP2 3071/4885LMNA 4560/4885 |
| US-20140066417-A1 | ANAESTHETIC FORMULATION | OPRL1, CNR1, CNR2 | NPC1L1 430/4885USP2 3071/4885LMNA 4560/4885 |
| US-20250032510-A1 | AMORPHOUS SOLID DISPERSION GANAXOLONE FORMULATION | PYGB, GYS2, CYP21A2 | NPC1L1 624/4885USP2 1757/4885LMNA 3549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.